bispecific antibodies

Pharma

J&J bispecific combo delivers 89% PFS benefit in myeloma

An 89% progression-free survival improvement and a 62% overall survival benefit topline Tecvayli and Talvey’s MonumenTAL-6 readout in earlier myeloma.

Angus Liu Jul 23, 2026 8:30am

Summit updates ivonescimab survival data ahead of PDUFA

Jul 22, 2026 10:58am

Why Legend Biotech stock fell 10% despite record Carvykti sales

Jul 20, 2026 11:11am

BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC

Jul 9, 2026 2:17pm

AbbVie, Genmab's Epkinly redeems itself in DLBCL

Jun 30, 2026 9:50am

At ASCO, China biotech industry cements its coming of age

Jun 3, 2026 8:50am